XAIRHIGH SIGNALRISK10-K

XAIR has added explicit going-concern warning language while experiencing a dramatic deterioration in its cash position and overall balance sheet.

The addition of substantial doubt about the company's ability to continue as a going concern represents a critical escalation in disclosed risk factors. This warning, combined with cash declining from $11.4M to $4.7M, signals potential liquidity constraints that could threaten operations or force asset sales.

Comparing 2025-06-20 vs 2024-06-24View on EDGAR →
FINANCIAL ANALYSIS

XAIR's financial position contracted significantly, with current assets falling 64% and cash reserves declining 59% to just $4.7M. While the company reduced both R&D and SG&A expenses by approximately 30% each and meaningfully improved operating cash flow losses, the overall balance sheet shrinkage of 47% alongside new going-concern disclosures suggests the company is burning through capital faster than anticipated. The simultaneous reduction in both assets and liabilities indicates potential restructuring or downsizing activities.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
-63.5%
$43.9M→$16.0M

Current assets declined 63.5% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-59%
$11.4M→$4.7M

Cash declined 59% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
-56.8%
$11.6M→$5.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-47.2%
$57.0M→$30.1M

Total assets contracted 47.2% — asset sales, write-downs, or balance sheet optimization underway.

Total Liabilities
Balance Sheet
-47.2%
$29.8M→$15.7M

Liabilities reduced 47.2% — deleveraging improves balance sheet strength and financial flexibility.

Stockholders Equity
Balance Sheet
-45.8%
$25.0M→$13.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
+31.8%
-$56.0M→-$38.2M

Operating cash flow surged 31.8% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-30.8%
$24.4M→$16.9M

R&D spending cut 30.8% — could signal cost discipline or concerning reduction in innovation investment.

SG&A Expense
P&L
-30.3%
$37.3M→$26.0M

SG&A reduced 30.3% — improved cost efficiency or headcount reduction improving operating margins.

Operating Income
P&L
+29.3%
-$63.0M→-$44.5M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2025-06-20
PRIOR — 2024-06-24
ADDED
There were 92,794,777 shares of common stock of the registrant, par value $ 0.0001 per share, outstanding as of June 19, 2025.
Our business is subject to the following principal risks and uncertainties: Risks Related to our Financial Position and Capital Requirements Our independent registered public accounting firm s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a going concern.
Numerous factors, including the incurring of significant losses, are relevant to our financial success and any or all such factors could have a disproportionate impact on our bottom line.
Healthcare legislative or regulatory reform measures, including government restrictions on pricing and reimbursement, may have a negative impact on our business and results of operations.
Our subsidiaries are exploring novel therapeutic processes with NO and once they develop product candidates, those product candidates are likely to be classified as pharmaceutical drugs by the FDA and thus face stringent regulation.
+7 more — sign up free →
REMOVED
Our business is subject to the following principal risks and uncertainties: Risks Related to our Financial Position and Capital Requirements Numerous factors, including the incurring of significant losses, are relevant to our financial success and any or all such factors could have a disproportionate impact on our bottom line.
If we are unable to raise sufficient capital to fund our operations, we may need to delay, reduce or eliminate certain research and development programs or other operations or sell some or all of our assets.
Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.
Our subsidiaries are exploring novel therapeutic processes with NO, and their product candidates are likely to be classified as pharmaceutical drugs by the FDA and thus face stringent regulation.
Risks Related to the Ownership of our Common Stock Stockholder disputes may be limited by the terms of our amended and restated certificate of incorporation.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →